Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAIRWAY: Faricimab in nAMD
NCT03038880Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of faricimab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Jan 2017; status: completed.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03038880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038880.